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Summary
 
Dendritic cells (DCs) are potent antigen-presenting cells that play a critical role in the initiation
of antitumor immune responses. In this study, we show that genetic modifications of a murine
epidermis-derived DC line and primary bone marrow–derived DCs to express a model antigen
 
b
 
-galactosidase (
 
b
 
gal) can be achieved through the use of a replication-deficient, recombinant
adenovirus vector, and that the modified DCs are capable of eliciting antigen-specific, MHC-
restricted CTL responses. Importantly, using a murine metastatic lung tumor model with syn-
geneic colon carcinoma cells expressing 
 
b
 
gal, we show that immunization of mice with the
genetically modified DC line or bone marrow DCs confers potent protection against a lethal
tumor challenge, as well as suppression of preestablished tumors, resulting in a significant sur-
vival advantage. We conclude that genetic modification of DCs to express antigens that are also
expressed in tumors can lead to antigen-specific, antitumor killer cells, with a concomitant re-
sistance to tumor challenge and a decrease in the size of existing tumors.
 
M
 
any tumor cells express epitopes on their surface that
provide a potential target for therapeutic vaccine
strategies that boost natural immune-mediated tumor de-
fense mechanisms (1–3). One of the challenges to develop-
ing antitumor vaccines is to develop strategies that focus
the immune response to the relevant tumor antigen. The
present study approaches this challenge by using replica-
tion-deficient, recombinant adenovirus (Ad)
 
1
 
 vectors to
transfer a gene coding for a model antigen (
 
b
 
-galactosidase;
 
b
 
gal) to dendritic cells (DCs) ex vivo, and administering
the genetically modified DCs to a syngeneic host. We
choose this approach to capitalize on the biologic proper-
ties of Ad vectors and DCs that are relevant to inducing an-
tigen-specific CTLs directed against specific antigens.
In this context, there is emerging evidence that, in some
circumstances, Ad vectors can act as adjuvants to boost
CTL response against heterologous transgenes (4–9). This
evidence, together with the knowledge that genes ex-
pressed by Ad vectors are expressed through the class I
pathway (10, 11), and that DCs are the most potent mem-
bers of the general class of antigen presenting cells (12–15),
led us to the hypothesis that genetically modifying DCs
with an Ad vector coding for a tumor antigen might help
focus the immune response to generating antigen-specific
CTLs.
With this background, the objectives of this study are to
assess the ability of Ad vectors to genetically modify DCs
ex vivo, and to assess the ability of DCs modified with
model antigens transferred to a syngeneic host to (
 
a
 
) induce
antigen-specific CTLs, (
 
b
 
) prevent tumors from developing
in animals challenged with tumor cells expressing the
model antigen, and (
 
c
 
) suppress the growth of preexisting
tumors composed of the same tumor cells. To accomplish
this, we used the XS52 BALB/c DC line (16, 17), as well
as freshly isolated DCs from bone marrow of BALB/c
mice. By using an Ad vector expressing 
 
b
 
gal and the
BALB/c syngeneic colon carcinoma cell line CT26.CL25
expressing 
 
b
 
gal (18), the data dramatically demonstrate that
administration of DCs modified to express 
 
b
 
gal induces
 
b
 
gal-specific CTLs, prevents tumor growth, and suppresses
the growth of preexisting tumors.
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Abbreviations used in this paper:
 
 Ad, adenovirus; 
 
b
 
gal, 
 
b
 
 galactosidase; DC,
dendritic cell; moi, multiplicity of infection.
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Materials and Methods
 
Mice and Cell Lines.
 
6–8-wk-old male BALB/c (H-2
 
d
 
) mice
were obtained from the Jackson Lab. (Bar Harbor, ME). Animals
were housed under specific pathogen-free conditions and treated
according to National Institutes of Health guidelines.
XS52 (H-2
 
d
 
) clone 4D, a DC line established from newborn
BALB/c mouse epidermis, was grown in complete RPMI media
(10% fetal bovine serum, 2 mM 
 
l
 
-glutamine, 100 
 
m
 
g/ml strepto-
mycin, and 100 U/ml penicillin) supplemented with recombinant
murine GM-CSF (2 ng/ml; Sigma Chemical Co., St. Louis,
MO) and supernatants collected from the stromal NS47 cell line
(both cell lines were provided by A. Takashima, University of
Texas Southwestern Medical Center, Dallas, TX; references 16,
17). CT26.WT (H-2
 
d
 
) is a clone of the 
 
N
 
-nitroso-
 
N
 
-methylure-
thane–induced BALB/c undifferentiated colon adenocarcinoma
(18). CT26.CL25 is a clone of CT26.WT that has been trans-
duced with the 
 
Escherichia coli
 
 
 
b
 
gal gene (both cell lines provided
by N.P. Restifo, National Cancer Institute, Bethesda, MD; refer-
ence 18). E22 cells, a clone of mouse thymoma EL4 (H-2
 
b
 
) cell
line transduced with the 
 
b
 
gal gene, was used as a negative control
in the CTL assay (E22 was provided by Y. Paterson, University
of Pennsylvania, Philadelphia, PA; reference 18). The SVBalb
(H-2
 
d
 
) fibroblast cell line was used as in vitro stimulator cells in
the CTL assay; this cell line is syngeneic to BALB/c mice (pro-
vided by L. Gooding, Emory University, Atlanta, GA; reference
19). CT26.WT and SVBalb were grown in complete RPMI me-
dia. CT26.CL25 and E22 were grown in complete RPMI con-
taining 400 
 
m
 
g/ml G418 (GIBCO BRL, Gaithersburg, MD).
 
Generation of Dendritic Cells In Vitro from Bone Marrow.
 
Primary
bone marrow DCs were obtained from mouse bone marrow pre-
cursors as described by Inaba et al. (20). In brief, lymphocyte- and
erythrocyte-depleted murine bone marrow cells harvested from
femurs and tibias were plated in completed RPMI media supple-
mented with recombinant murine GM-CSF (100 U/ml) and re-
combinant murine interleukin 4 (20 ng/ml; Genzyme, Farming-
ton, MA). On days 2 and 4, nonadherent granulocytes were
gently removed and fresh media was added. On day 6, loosely ad-
herent proliferating DC aggregates were dislodged and replated.
On day 8 of culture, released, mature, nonadherent cells with the
typical morphological features of DCs were used for in vitro phe-
notypic and functional analysis as well as for the immunization of
mice. For phenotypic analysis, the nonadherent cells from the
bone marrow culture were stained with a panel of antibodies
characteristic of DCs, including CD11b (No. 01714D, PharMin-
gen, San Diego, CA), CD44 (No. 01225A, PharMingen), and
IA
 
d
 
 (No. 06274D, PharMingen) and then quantified by flow cy-
tometry. Isotype-matched monoclonal antibodies were used as
controls. Bone marrow DCs were also tested for their ability to
activate naive allogeneic T cells in vitro using a mixed lympho-
cyte reaction assay (20).
 
Ad Vector–mediated Gene Transfer and Expression in DCs In Vitro.
 
The replication-deficient Ad vectors used in this study are E1a
 
2
 
,
partially E1b
 
2
 
, and partially E3
 
2
 
 vectors based on human Ad5
(21, 22). The construction of these Ad vectors have been de-
scribed previously, including vectors expressing no transgene
(AdNull) and the 
 
E. coli
 
 
 
b
 
gal gene (Ad
 
b
 
gal; reference 23). All Ad
vectors were propagated in 293 cells, purified by two rounds of
CsCl density centrifugation, dialyzed, and stored at 
 
2
 
70
 
8
 
C as
previously described (21, 22). The titer of viral stock was deter-
mined by plaque-forming assay using 293 cells. All vector prepa-
rations were demonstrated to be free of replication competent ad-
enovirus (24).
To assess the ability of Ad vectors to transfer and express genes
in DCs in vitro, the XS52 DC line and primary bone marrow
DCs were infected with Ad
 
b
 
gal or AdNull for 2 h at various
multiplicities of infection (moi). 24 h later, 
 
b
 
gal expression was
quantified by flow cytometry using fluorescein di-
 
b
 
-galactoside
(Molecular Probes, Inc., Eugene, OR; reference 25). Labeling
with propidium iodide (1 
 
m
 
g/ml) was used to facilitate live/dead
cell discrimination.
 
Induction of Antigen-specific CTLs.
 
To determine if the admin-
istration of DCs by in vitro infection with Ad
 
b
 
gal would evoke
 
b
 
gal-specific CTLs, the XS52 DC line or primary bone marrow
DCs were infected with Ad
 
b
 
gal or AdNull (moi 100) as de-
scribed above. BALB/c mice were immunized once by subcuta-
neous injection of 3 
 
3
 
 10
 
5
 
 modified DCs suspended in 100 
 
m
 
l
HBSS. Spleens were removed 14 d after DC inoculation, the in
vivo primed splenocytes were pooled and cocultured (2 
 
3
 
 10
 
6
 
/
ml) with irradiated (5,000 rad) syngeneic SVBalb cells (2 
 
3
 
 10
 
5
 
/
ml) pulsed with the synthetic 
 
b
 
gal peptide (1 
 
m
 
M) in a 6-well
plate (5 ml/well). After 5 d of coculture, the in vitro restimulated
viable splenocytes were assayed in a 
 
51
 
Cr–release assay for specific
cell lysis against a variety of target cells, including syngeneic cell
lines CT26.WT, 
 
b
 
gal-expressing CT26.CL25, and 
 
b
 
gal peptide-
pulsed CT26.WT, as well as a MHC-mismatched, 
 
b
 
gal-expressing
E22 (H-2
 
b
 
) cell line. The 
 
b
 
gal peptide used in the CTL studies is
the nanomer TPHPARIGL (residues 876–885) that is naturally
presented by the H-2 L
 
d
 
 molecule (26). The peptide was synthe-
sized (Biosynthesis, Lewisville, TX) to a purity 
 
.
 
99% as deter-
mined by high pressure liquid chromatography and amino acid
analysis. The 
 
51
 
Cr–release assay was performed as previously de-
scribed (9, 27).
 
Protection against Lethal Tumor Challenge after XS52 DC Immuni-
zation.
 
To evaluate the ability of the XS52 DC line infected
with Ad
 
b
 
gal to protect against a tumor challenge, 6–8-wk-old
BALB/c mice were immunized with 3 
 
3
 
 10
 
5
 
 Ad
 
b
 
gal-modified
(moi 100, 24 h, 37
 
8
 
C) XS52 (referred to as XS52-Ad
 
b
 
gal) in 100
 
m
 
l HBSS injected subcutaneously in the left lower quadrant of
the ventral abdominal wall (
 
n
 
 
 
5
 
 4). Control animals received ei-
ther no XS52 (
 
n
 
 
 
5
 
 5), XS52 infected with AdNull (XS52-AdNull;
 
n
 
 
 
5
 
 2), or XS52-Ad
 
b
 
gal that were frozen and thawed four times
before injection to lyse the cells (
 
n
 
 
 
5
 
 5). 2 wk later, naive and
XS52-immunized mice were challenged with syngeneic 10
 
5
 
CT26.CL25 murine colon carcinoma cells injected intravenously
through the jugular vein. This model generated multiple diffuse
pulmonary metastases that were highly lethal. 12–16 d after tu-
mor challenge, the mice were killed, their lungs harvested, fixed
in 4% paraformaldehyde, and stained for 
 
b
 
gal expression with
X-Gal (5-bromo-4-chloro-3-indolyl-
 
b
 
-
 
d
 
-galactopyranoside). To
quantify the tumor burden, the number of blue staining lung me-
tastases was carefully counted in a blinded fashion under a dissect-
ing microscope. Only metastatic deposits 
 
<
 
250 could be reliably
enumerated; lungs with 
 
.
 
250 deposits were assigned an empirical
number of 250.
To evaluate if an effective antitumor protection would trans-
late into significant prolongation of survival, an identical, parallel
experiment was performed in which the mice (
 
n
 
 
 
5
 
 9 in XS52
Ad
 
b
 
gal group; 
 
n
 
 
 
5
 
 10 in XS52-AdNull group) were not killed
after XS52 immunization and tumor challenge, but were followed
for survival. In addition, to evaluate if the antitumor immunity
was 
 
b
 
gal specific, another group of mice (
 
n
 
 
 
5
 
 10) immunized
with XS52-Ad
 
b
 
gal was challenged with CT26.WT tumor cells
that did not express 
 
b
 
gal and followed for survival.
 
Suppression of Preestablished Lung Metastases by XS52 DC Line
Immunization. To mimic the clinical scenario more closely, we1249 Song et al.
evaluated whether preexisting lung metastases could be sup-
pressed after immunization with XS52 cell line modified with
Adbgal (n 5 4) or AdNull (n 5 4). BALB/c mice were first in-
jected with 3 3 104 CT26.CL25 tumor cells intravenously to
generate multiple lung metastases. 3 d later, tumor-bearing mice
were either left untreated, or treated with subcutaneous injections
of XS52-AdNull (n 5 4), XS52-Adbgal (n 5 4), or XS52-Adb-
gal that were frozen and thawed four times to lyse the cells (n 5
3). 20 d after tumor implantation, the animals were killed and the
lungs evaluated for the presence of metastases in a similar fashion
as described in the prevention experiment.
To evaluate if treatment of preestablished lung metastases
would result in a prolongation of survival in tumor-bearing ani-
mals, a separate but similar experiment was performed in which
the mice were not sacrificed following treatment with XS52 cells
modified with Adbgal (n 5 7) or AdNull (n 5 5), but were fol-
lowed for survival. To evaluate if the treatment effect was bgal
specific, a group of mice (n 5 6) with preestablished CT26.WT
tumors that did not express bgal was treated with XS52 cells
modified with Adbgal and followed for survival.
Protection against Lethal Tumor Challenge after Bone Marrow DC
Immunization. To evaluate the ability of bone marrow DCs in-
fected with Adbgal to protect against a tumor challenge, 6–8-wk-old
BALB/c mice (n 5 8/group) were immunized with 3 3 105
bone marrow DC–Adbgal in 100 ml HBSS injected subcutane-
ously in the left lower quadrant of the ventral abdominal wall.
Control animals received either no bone marrow DCs, bone
marrow DCs infected with AdNull (bone marrow DC–AdNull),
or bone marrow DC–Adbgal that were frozen and thawed four
times before injection to lyse the cells. 2 wk later, naive and im-
munized mice were challenged with syngeneic 105 CT26.CL25
murine colon carcinoma cells injected intravenously through the
jugular vein. The mice were then followed for survival. In addi-
tion, to evaluate if the antitumor immunity was bgal specific, an-
other group of mice (n 5 8) immunized with bone marrow DC–
Adbgal was challenged with CT26.WT tumor cells that did not
express bgal and followed for survival.
Suppression of Preestablished Lung Metastases by Bone Marrow DC
Immunization. To mimic the clinical scenario more closely, we
evaluated whether preexisting lung metastases could be sup-
pressed after immunization with bgal-expressing bone marrow
DCs. BALB/c mice were first injected with 3 3 104 CT26.CL25
tumor cells intravenously to generate multiple lung metastases. 3 d
later, tumor-bearing mice (n 5 8/group) were either left un-
treated, or treated with subcutaneous injections of bone marrow
DC–AdNull, bone marrow DC–Adbgal, or bone marrow DC–
Adbgal that were frozen and thawed four times to lyse the cells.
The mice were then followed for survival. To evaluate if the
treatment effect was bgal specific, a group of mice (n 5 8) with
preestablished CT26.WT tumors that did not express bgal was
treated with bone marrow DC–Adbgal and followed for survival.
Statistical Analysis. All animal experiments used a minimum
of four animals except for the XS52 prevention experiment in
which the XS52-AdNull group had only two animals (inadver-
tently, two animals in this group were left out of the study; in a
repeat study, this group had five animals). All studies were re-
peated at least twice with similar results. Quantitative results are
expressed as mean 6 standard error of the mean. Statistical analy-
sis was performed using the unpaired two-tailed Student’s t test,
with the exception of the survival data which was analyzed using
the log-rank test (28).
Results
Adenoviral Transduction of XS52 Cells In Vitro. To evaluate
the ability of Ad vectors to transfer and express genes in
XS52 DCs, XS52 DCs were infected with Adbgal, and the
cells were quantified for bgal activity at 24 h after infection
by flow cytometry. Although naive XS52 (Fig. 1, A) and
AdNull-infected XS52 (B) showed only background levels
of bgal activity, expression of bgal was readily detected in
the majority (73%) of XS52 infected with Adbgal at moi of
100 (C), demonstrating that successful gene transfer and ex-
pression can be achieved in DCs using an Ad vector. Paral-
lel studies carried out using other moi demonstrated 14%
XS52 cells expressing bgal with a moi of 30 and 62% at a
moi of 300 (not shown). On the basis of these studies, all
subsequent studies were carried out with a moi of 100.
Induction of CTLs Using Ad Vector–transduced XS52
Cells. To determine if Ad-mediated gene expression in
DCs would induce an antigen-specific CTL response in
vivo, BALB/c mice were first immunized with 3 3 105
XS52 cells that had been modified in vitro with AdNull- or
Adbgal-infection. Splenocytes from immunized mice were
then harvested and stimulated in vitro with bgal peptide
and were then assayed for specific cell lysis against a panel
of target cells in a standared 51Cr–release assay. Although
immunization of naive XS52 or XS52-AdNull infected
cells did not result in a measurable bgal-specific CTL re-
sponse (Fig. 2, A), significant lysis of bgal-expressing
CT26.CL25 target cells or bgal peptide-pulsed CT26.WT
target cells were observed in mice immunized with XS52-
Adbgal (B). Only negligible lysis of non–bgal-expressing
CT26.WT target cells was detected in mice immunized
with XS52-Adbgal, indicating that the cellular immune re-
sponse induced by XS52-Adbgal was bgal specific. This
specific cytotoxicity was mediated predominantly by MHC-
restricted CTLs rather than by natural killer cells since E22,
an MHC-mismatched (H-2b), bgal-expressing murine tu-
mor cell line, was not significantly lysed in the same assay.
Protection against Lethal Tumor Challenge after Immunization
with the Adbgal-modified XS52 DC Line. Between 12 and
Figure 1. Ad vector–mediated gene transfer and expression of bgal to
the murine XS52 DC line in vitro. The XS52 cells were infected in vitro
with an Ad vector expressing bgal (Adbgal) or the AdNull control vector
at moi of 100 for 2 h. 24 h later, bgal expression was quantified by flow
cytometry using fluorescein di-b-galactoside. Cells were stained with
propidum iodide to facilitate discrimination among live and dead cells.
For all panels, the y-axis reflects DC number and the x-axis reflects log
fluorescein intensity. The K gate has been set according to the negative
control in A. The percentage of bgal-expressing DCs was determined by
the right shift of the curve along the K gate. (A) Uninfected XS52 cells.
(B) XS52 infected with AdNull. (C) XS52 infected with Adbgal.1250 Antitumor Immunity induced by Ad-transduced DCs
16 d after an intravenous tumor challenge, tumor-bearing
mice which were not treated showed signs of respiratory
distress and developed hemorrhagic pleural effusion and
diffuse lung metastases (Fig. 3, A). Similarly, mice which
were previously immunized with XS52-AdNull developed
numerous lung metastases (B). In marked contrast, mice
which were previously immunized with XS52-Adbgal
showed very few visible lung metastases under the dissect-
ing microscope (C and D), indicating that immunization of
mice with DCs genetically modified to express the bgal
model antigen could effectively protect against a lethal tu-
mor challenge. Quantitative analysis of the number of lung
metastases confirmed the significant difference between XS52-
Adbgal–immunized mice and untreated mice (P ,0.0001)
or XS52-AdNull–immunized mice (E). Further, immuni-
zation with XS52-Adbgal that had been frozen and thawed
did not confer protection when compared to untreated and
XS52-AdNull–immunized groups (P .0.1; not shown),
i.e., live DCs were a prerequisite to generate an effective
antitumor immunity.
Figure 2. Induction of CTL
response in BALB/c mice after
in vivo administration of Adb-
gal-infected XS52 DCs. The
XS52 DCs were transduced in
vitro with AdNull or Adbgal at
moi of 100 for 2 h. 24 h later, 3 3
105 cells were administered sub-
cutaneously to syngeneic BALB/
c mice. 14 d later, splenocytes
harvested from immunized mice
were stimulated for 5 d in vitro
with syngeneic fibroblasts
(SVBalb) pulsed with a bgal peptide, and then assayed for specific cell lysis against three syngeneic colon carcinoma target cells (parental CT26.WT cells,
bgal-expressing CT26.CL25 cells, or CT26.WT pulsed with bgal peptide in vitro [CT26.WT-bgal peptide]) as well as the E22 bgal-expressing alloge-
neic tumor cell line. (A) CTL response in mice immunized with XS52 DCs infected with AdNull. (B) CTL response in mice immunized with XS52
DCs infected with Adbgal.
Figure 3. Protection against lethal tumor challenge using modified XS52 DCs. Shown are examples and
quantitative data of protection against lung metastases after XS52 immunization, using the bgal as a model anti-
gen, BALB/c mice, and syngeneic CT26.CL25 colon carcinoma cells (expressing bgal). XS52 cells were genet-
ically modified by in vitro infection with AdNull or Adbgal (moi 100, 2 h). 24 h after infection, 3 3 105
XS52-AdNull or XS52-Adbgal were injected subcutaneously to syngeneic BALB/c mice. 14 d later, the mice
were challenged with intravenous administration of 3 3 105 CT26.CL25 cells. 12–16 d after tumor challenge,
the mice were killed, their lungs harvested, fixed, and stained for bgal expression with X-Gal. (A) Example of
lungs from a nonimmunized mouse. (B) Example of lungs from a mouse immunized with XS52-AdNull. (C
and D) Examples of lungs from mice immunized with XS52-Adbgal. (E) Quantification of the number of lung
metastases in nonimmunized, XS52-AdNull–immunized and XS52-Adbgal–immunized mice after tumor chal-
lenge. Using a dissecting microscope, surface blue-staining (bgal1) lung metastases were enumerated. Each data
point represents an individual animal. Only metastatic deposits <250 could be reliably enumerated; lungs with
.250 metastases were assigned an empirical number of 250.1251 Song et al.
implantation (Fig. 4). In contrast, mice which had been pre-
immunized with XS52-Adbgal exhibited a markedly pro-
longed survival (P ,0.0001, Fig. 4), consistent with the
findings that XS52-bgal–immunized mice had far fewer
lung metastases than the control treatment groups after a
tumor challenge. Importantly, no protection was conferred
by XS52-Adbgal immunization against CT26.WT tumor
cells which did not express bgal (P .0.06; not shown),
suggesting that the antitumor immunity generated by ad-
ministration of the Adbgal-modified DCs was antigen (bgal)-
specific.
Suppression of Preestablished Lung Metastases after XS52-
Adbgal Treatment. To evaluate if tumor protection after
DC immunization could be extended to a more stringent
and clinically relevant model, Adbgal-modified XS52 were
used to treat mice with preexisting tumors. In this experi-
ment, diffuse lung metastases were first generated in
BALB/c mice by intravenous administration of 3 3 104
CT26.CL25 tumor cells. 3 d after tumor implantation, the
mice were either left untreated or were treated with subcu-
taneous administration of 3 3 105 XS52–AdNull modified
cells or XS52-Adbgal–modified cells. Tumor-bearing mice
that were not immunized (Fig. 5, A) or those that were im-
munized with the control DCs (XS52-AdNull; B) exhib-
ited multiple lung metastases 20 d after tumor implantation.
In contrast, tumor-bearing mice which received XS52-
Adbgal treatment demonstrated a striking reduction in the
Figure 4. Survival advantage in mice immunized with modified XS52
cells after a tumor challenge. Animals were immunized with XS52 cells
modified with Adbgal or AdNull. The experiment is similar to that de-
picted in Fig. 3, except that the animals were not killed but were fol-
lowed for survival. The data is expressed as percent survival as a function
of time. Survival for the mice immunized with XS52-Adbgal was signifi-
cantly prolonged over the XS52-AdNull control, as determined by log-
rank analysis of the Kaplan-Meier survival curves (P ,0.0001).
Figure 5. Suppression of preestablished lung metastases by administration of modified XS52 DCs. Shown
are examples and quantitative data of treatment effect on preestablished lung metastases induced by XS52-
Adbgal immunization. 3 d after the establishment of diffuse lung metastases in BALB/c mice with intravenous
administration of 3 3 104 CT26.CL25 cells, 3 3 105 XS52-AdNull or XS52-Adbgal were administered sub-
cutaneously to the tumor-bearing mice. 20 d after tumor implantation, the mice were killed, and their lungs
were harvested, fixed, and stained for bgal expression with X-Gal. (A) Example of lungs from a nonimmunized
mouse. (B) Example of lungs from a mouse receiving XS52-AdNull treatment. (C and D) Examples of lungs
from mice receiving XS52-Adbgal treatment. (E) Quantification of the number of lung metastases in un-
treated, XS52-AdNull– and XS52-Adbgal–treated mice with preestablished lung metastases. Using a dissecting
microscope, surface blue-staining (bgal1) lung metastases were enumerated. Each data point represents an in-
dividual animal. Only metastatic deposits <250 could be reliably enumerated; lungs with .250 metastases
were assigned an empirical number of 250.
The metastatic lung tumor model in this study was
highly lethal, such that mice immunized with the negative
control DCs (XS52-AdNull) succumbed to advanced pul-
monary malignancy an average of two wk after tumor1252 Antitumor Immunity induced by Ad-transduced DCs
number of metastases (C and D), demonstrating that DCs
genetically modified to express a tumor antigen could ef-
fectively suppress preexisting tumors. Quantitative analysis
of the number of metastatic nodules confirmed the signifi-
cant treatment differences between XS52-Adbgal–treated
group and the control groups (P ,0.009; E). In contrast,
XS52-Adbgal cells that had been lysed by repeated freezing
and thawing did not confer any therapeutic effect when com-
pared to untreated or XS52-AdNull–treated animals (P .0.4;
not shown).
In cancer treatment, any observed treatment response
becomes even more meaningful if it translates into a sur-
vival advantage. To evaluate if the reduction in the number
of lung metastases in mice treated with XS52-Adbgal con-
ferred a survival advantage, a group of animals were fol-
lowed for survival. Tumor-bearing mice that were treated
with XS52-Adbgal lived significantly longer than the ani-
mals in the negative control groups (P ,0.002, Fig. 6).
Consistent with the observation in the prevention experi-
ment, XS52-Adbgal treatment did not suppress preestab-
lished non–bgal-expressing CT26.WT tumors (not shown),
again suggesting that the therapeutic effect is antigen
(bgal)-specific (P .0.2). Further, lysed XS52-Adbgal cells
did not confer a survival advantage as compared to un-
treated mice or mice treated with XS52-AdNull (P .0.8;
not shown).
Adenovirus Vector Modification of Primary Bone Marrow
DCs. To evaluate if the observations made using XS52
cell line could also be reproduced using primary DCs, DC
modification, tumor prevention, and tumor treatment ex-
periments were carried out similar to that with the XS52
DC line. Bone marrow DC from BALB/c mice were iso-
lated and expanded ex vivo for 7 d, followed by their char-
acterization using composite criteria of typical morphology,
cell surface markers, and functional mixed lymphocyte re-
action assay. Cell surface phenotypic analysis by flow cytome-
try revealed high frequency of expression of CD11b (two sep-
arate preparations, 72, 73%), CD44 (98, 99%), and MHC
class II antigen IAd (75, 80%; not shown). Consistent with
the known function of DCs, as few as 100 DCs induced an
allogenic T lymphocyte proliferation in a mixed lympho-
cyte reaction with stimulation indices of .20 (not shown).
To evaluate the ability of Ad vectors to transfer and ex-
press genes in primary bone marrow DCs, Adbgal was used
to infect bone marrow DCs an moi of 100, and the cells
were quantified for bgal activity at 24 h after infection by
flow cytometry. Similar to the findings with XS52-Adbgal
(Fig. 1, C), expression of bgal was readily detectable (95%)
in bone marrow DCs infected with Adbgal (Fig. 7, C), but
not in naive bone marrow DCs (A) or bone marrow DCs
infected with AdNull (B), demonstrating that Ad vectors
can transfer and express genes in primary DCs. Parallel
studies carried out using other moi demonstrated 17% bone
marrow DC cells expressing bgal with an moi of 30 and
96% at an moi of 300 (not shown). Based on these studies,
all subsequent studies were carried out at an moi 100.
Induction of CTL Response In Vivo Using Ad Vector–trans-
duced Primary Bone Marrow DCs. To evaluate if geneti-
cally modified primary bone marrow DCs would induce an
antigen-specific CTL response in vivo, splenocytes from mice
immunized with subcutaneous administration of bone mar-
row DCs transduced with Adbgal were stimulated in vitro
with bgal peptide and were then evaluated for specific cell
lysis against a panel of target cells in a standard 51Cr–release
assay. Immunization with bone marrow DC–Adbgal cells
induced a bgal-specific CTL response (Fig. 8, B), whereas
the negative control bone marrow DC–AdNull cells did
not (A). Only negligible lysis of non–bgal-expressing
CT26.WT target cells were detected in mice immunized
with bone marrow DC–Adbgal cells, indicating that the
cellular immune response induced was bgal specific. This
specific cytotoxicity was mediated predominately by MHC-
restricted CTLs rather than by natural killer cells since E22,
an MHC-mismatched (H-2b) bgal-expressing murine tu-
mor cell line, was not significantly lysed in the same assay.
Figure 6. Survival advantage in tumor-bearing mice treated with mod-
ified XS52 cells. Animals were immunized with XS52 cells modified with
Adbgal or AdNull. The experiment is similar to that depicted in Fig. 5,
except that the animals were not killed but were followed for survival.
The data is expressed as percentage of survival as a function of time. Sur-
vival for mice which were treated with XS52-Adbgal was significantly
prolonged over the XS52-AdNull control, as determined by log-rank
analysis of the Kaplan-Meier survival curves (P ,0.002).
Figure 7. Ad vector–mediated gene transfer and expression of bgal in
bone marrow DC (BMDC) in vitro. The primary murine DCs were in-
fected in vitro with Adbgal or AdNull control vector at moi of 100 for 2 h.
24 h later, bgal expression was quantified by flow cytometry using fluo-
rescein di-b-galactoside. For all panels, the y-axis reflects DC number and
the x-axis reflects log fluorescein intensity. The percentage of bgal-
expressing DCs was determined by the right shift of the curve along the K
gate. (A) Uninfected bone marrow DCs. (B) Bone marrow DCs infected
with AdNull. (C) Bone marrow DCs infected with Adbgal.1253 Song et al.
Prevention against Lethal Tumor Challenge after Bone Marrow
DC Immunization. Consistent with the studies using XS52-
Adbgal modified DCs, BALB/c mice that were immunized
with bone marrow DC–Adbgal before challenge with tu-
mor cells were effectively protected against the tumor chal-
lenge, as evidenced by a prolonged survival in the bone
marrow DC–Adbgal group compared to the bone marrow
DC–AdNull group (P ,0.0001, Fig. 9). In contrast, mice
immunized with bone marrow DC–Adbgal were not pro-
tected against a challenge by CT26.WT cells (P .0.9; not
shown), indicating that the immune response was bgal spe-
cific.
Suppression of Preestablished Lung Metastases by Bone Marrow
DC Immunization. Mice with preexisting lung metastases
that received bone marrow DC–Adbgal treatment lived
significantly longer than the bone marrow DC–AdNull
control group (P ,0.002, Fig. 10), demonstrating that pri-
mary DCs that are genetically modified to express the tu-
mor antigen could suppress preestablished tumors. As in the
prevention experiment, bone marrow DC–Adbgal immu-
nization had no therapeutic effect on CT26.WT tumors
that did not express bgal (P .0.5; not shown), indicating
that the antitumor effect was tumor antigen specific. Simi-
larly, lysed bone marrow DCs were ineffective in prolong-
ing survival compared to control groups (P .0.1; not
shown).
Discussion
This study evaluates the use of an adenovirus gene trans-
fer vector to deliver a model antigen into DCs in vitro, and
the ability of subsequent in vivo administration of these ge-
Figure 8. Induction of CTL
response in BALB/c mice after
in vivo administration of bone
marrow DCs infected with Adb-
gal. Bone marrow DCs were
transduced in vitro with AdNull
or Adbgal at moi of 100 for 2 h.
24 h later, 3 3 105 cells were ad-
ministered subcutaneously into
syngeneic BALB/c mice. 14 d
later, splenocytes harvested from
immunized mice were stimu-
lated for 5 d in vitro with synge-
neic fibroblasts (SVBalb) pulsed
with bgal peptide and then assayed for specific cell lysis against three syngeneic colon carcinoma target cells (parental CT26.WT cells, bgal-expressing
CT26.CL25 cells, or CT26.WT pulsed with bgal peptide in vitro [CT26.WT-bgal peptide]) as well as the E22 bgal-expressing allogeneic tumor cell
line. (A) CTL response in mice immunized with bone marrow DCs infected with AdNull. (B) CTL response in mice immunized with bone marrow
DCs infected with Adbgal.
Figure 9. Survival advantage in mice immunized with modified bone
marrow DCs after a tumor challenge. Animals were immunized with
bone marrow DCs modified with Adbgal or AdNull, followed 14 d later
by intravenous challenge of 105 CT26.CL25 tumor cells. The animals
were not killed, but were followed for survival. The data is expressed as
percentage of survival as a function of time. Survival for the mice immu-
nized with bone marrow DC–Adbgal was significantly prolonged over
the bone marrow DC–AdNull control, as determined by log-rank analysis
of the Kaplan-Meier survival curves (P ,0.0001).
Figure 10. Survival advantage in tumor-bearing mice treated with modi-
fied bone marrow DCs. 3 d after the establishment of lung metastases with
intravenous administration of 3 3 104 CT26.CL25 tumor cells, BALB/c
mice were immunized with bone marrow DCs modified with Adbgal or
AdNull. The animals were not killed, but were followed for survival. The
data is expressed as percent survival as a function of time. Survival for
mice that were treated with bone marrow DC–Adbgal was significantly
prolonged over the bone marrow DC–AdNull control, as determined by
log-rank analysis of the Kaplan-Meier survival curves (P ,0.002).1254 Antitumor Immunity induced by Ad-transduced DCs
netically modified DCs to induce tumor antigen–specific
antitumor immunity. The data demonstrate that an Ad
vector encoding bgal as a model antigen can effectively
transfer and express the transgene in a DC line and primary
bone marrow DCs. In vivo administration of these modi-
fied DCs elicits an MHC-restricted, antigen-specific CTL
response, protects syngeneic mice against tumor challenge,
and suppresses preexisting lethal tumors. Importantly, a re-
duction in tumor burden in all studies was translated into
significant survival advantage. These observations under-
score the ability of genetically modified DCs to effectively
present tumor antigens and induce immunity against tu-
mors. With the discovery and definition of more tumor an-
tigens, this strategy of genetic manipulation of DCs to ex-
press specific tumor antigens may provide an effective
treatment for an increasing number of malignancies.
Genetic Manipulation of DCs. DCs are the most potent
professional antigen presenting cells that are capable of ini-
tiating T cell–dependent immune responses (12–15). Strat-
egies that have been used to adapt this biologic potential to
tumor therapy includes manipulating DCs by coculturing
(pulsing) DCs with whole tumor antigens, defined tumor
antigenic peptides, or total RNA from tumor cells (29–38).
Using such approaches, it has been shown that effective an-
tigen-specific immunity and antitumor responses can be
elicited (29–38). Genetically modifying DCs by genes cod-
ing for specific tumor antigens to DCs has potential advan-
tages. First, the genetically modified DCs may present pre-
viously unknown epitopes in association with different
MHC molecules. Second, gene transfer to DCs ensures
that the gene product is endogenously processed, leading to
the generation of MHC class I–restricted CTLs which is
the effector arm of cell-mediated immune response against
tumor cells. Third, by using viral vectors to modify DCs in
vitro, there is far less administration of viral proteins, in
contrast to direct in vivo vaccination with viral vectors,
thus minimizing the generation of neutralizing antibodies
that prevent repeat treatment (27, 39).
Theoretically, direct gene transfer to DCs has advantages
in generating CTLs toward the protein coded by the trans-
gene, in that the gene will be transferred to the DC nu-
cleus, expressed, and presented in the context of class I
MHC for the immune system to recognize as self or non-
self (10, 11). In this regard, there is emerging evidence that
when Ad vectors expressing heterologous transgenes are
administered in vivo the Ad functions as an “adjuvant” to
enhance cellular immune responses against the heterolo-
gous transgene product, including the generation of trans-
gene product–specific CTLs (4–9). It is not known
whether or not this is secondary to in vivo transfer of the
transgene to DCs in the local milieu, or is by other mecha-
nisms. However, independent of the process by which Ad
vectors induce CTLs against heterologous transgenes, the
data in the present study clearly demonstrate that when an
Ad vector expressing a heterologous transgene is used to
transfer the transgene to DCs in vitro, subsequent transfer
of the genetically modified DCs to a syngeneic host will re-
sult in the induction of CTLs against the heterologous
transgene product.
Different gene transfer approaches have been explored to
use genetically modified DCs in antitumor therapy (40–
44). Several groups have reported the successful transduc-
tion of human DCs in vitro by retrovirus vectors encoding
a model antigen (bgal) and tumor antigens including the
melanoma MART-1 antigen and the human epithelial tu-
mor antigen mucin (40, 41, 43). Brossart et al. (44) has re-
cently shown that adenovirus and vaccinia virus vectors
could transfer a model antigen (ovalbumin) into murine
immortalized and primary DCs, and that the virus–infected
DCs elicited stronger antigen-specific CTL response in
vivo than immunization with DCs which were pulsed with
ovalbumin peptide or protein. Importantly, immunization
of mice twice with the virus-infected immortalized DCs
protected the mice from a lethal challenge with tumor cells
expressing ovalbumin. Consistent with these observations,
the present study demonstrated that a single immunization
of genetically modified DC line and primary DCs elicited
antigen-specific CTL responses in vivo that were highly ef-
fective in protecting the mice from a lethal tumor chal-
lenge. Importantly, our study also shows that treatment of
tumor-bearing mice with a single immunization of geneti-
cally modified DCs led to a marked suppression of the
growth of established tumors. To further improve the ther-
apeutic efficacy of this strategy, the codelivery of cytokine
gene and tumor antigen gene into DCs and/or repeat im-
munization of DCs may enhance the antigen-specific anti-
tumor immunity.
Clinical Relevance. In addition to demonstrating that Ad
vector–transduced DCs could generate an antigen-specific
CTL response that protected immunized animals against a
tumor challenge, this study also showed that the genetically
modified DCs effectively suppress preestablished, rapidly
growing metastatic tumors. The latter observation is clini-
cally relevant since patients have preexisting tumors at the
time of presentation and the Achilles heel of conventional
cancer treatment today remains the failure to effectively
control metastatic disease. In this regard, one clinical sce-
nario to which this study is particularly relevant is one of
micrometastases which are often present at the time of pri-
mary detection of many malignancies such as breast, colon,
and lung cancer (45, 46). A possible clinical strategy to ap-
proach this problem would be to modify autologous DCs
from such patients using an Ad vector encoding the rele-
vant tumor antigen, and then administering the genetically
modified DCs as adjuvant treatment after primary therapy.
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